ClinicalTrials.gg
Not yet recruitingNCT07742540Updated Aug 3, 2026

The Cardiovascular Effects of Patent Foramen Ovale in Hypoxia

An observational study in Patent Foramen Ovale (PFO) and High Altitude Pulmonary Edema, sponsored by University of Texas Southwestern Medical Center. Not yet recruiting. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by University of Texas Southwestern Medical Center · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Before birth, the foramen ovale is a normal opening in the heart that allows blood to flow from the mother to the baby. After birth, this opening usually closes. However, in up to 38% of the population it does not fully close and is then called a patent foramen ovale (PFO). Having a PFO allows venous (blue) blood to mix with arterial (red) blood in the heart, which can lower blood oxygen levels. The mixing of blood has been suggested to be greater during exercise and with exposure to high-altitude. Also, people with a PFO may be a greater risk for severe altitude sickness, specifically involving the collection of fluid in the lungs which makes breathing very difficult - this is called high-altitude pulmonary edema (HAPE).

No study has directly measured the pressure difference across the heart which is required for the mixing of blood during exercise or at high-altitude. The present study will directly measure the pressure difference across the heart, as well as blood flow through the PFO during rest and exercise in simulated high altitude in adults with and without a PFO and a previous history of severe altitude sickness. The study will test the hypothesis that elevations in pulmonary artery pressure during exposure to hypoxia will not elicit a pressure gradient, and thus blood flow, across the PFO neither at rest nor during exercise.

02

Conditions studied

  • Patent Foramen Ovale (PFO)
  • High Altitude Pulmonary Edema

Keywords

  • hypoxia
  • altitude
  • heart
  • high altitude pulmonary edema
  • patent foramen ovale
  • exercise
  • pulmonary artery pressure
  • intracardiac pressures
  • right-to-left shunt
03

In context

Foramen Ovale, Patent

136 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.

This study's planned enrollment of 50 is below the median of 254 across 59 observational studies indexed under Foramen Ovale, Patent.

Browse Foramen Ovale, Patent studies →

Lead sponsor

University of Texas Southwestern Medical Center is the lead sponsor of 1,010 studies on the registry; 199 are open to participants now.

Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals with documented history of high-altitude pulmonary edema and with or without a patent foramen ovale

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females age > 18 but \< 60 years of age at the time of signing the .
  • Medically documented episode of noncardiogenic pulmonary edema occurring after exposure to hypoxia at high altitude.
  • No other associated congenital cardiac or vascular abnormalities.
  • Physically active, and able to perform endurance exercise.

Exclusion criteria

Exclusion Criteria:

  • Do not otherwise meet the inclusion criteria.
  • Cardiac- or pulmonary-related medications.
  • Known history of anemia, iron deficiency, iron supplementation (oral or intravenous) in the preceding 60 days.
  • Systemic anticoagulation or aspirin use that cannot be temporarily held for the study.
  • Non-cardiopulmonary disorders that adversely influence exercise ability (e.g. arthritis or peripheral vascular disease).
  • Engaging in vigorous physical activity [≥1 hour at ≥6 mets] at ≥8,000 ft for >2 days per week over the preceding 4 weeks, and residing at ≥8,000 ft for 3 or more consecutive nights in the preceding 30 days.
  • History of any recent illnesses (e.g. viral respiratory infections) within 4 weeks of testing.
  • Women who are pregnant (urine pregnancy test given to all women of childbearing age at the time of testing).
  • Other conditions that would limit the patient's ability to complete the study procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • HAPE+PFO

    Adults with documented history of high-altitude pulmonary edema and a patent foramen ovale

  • HAPE

    Adults with documented history of high-altitude pulmonary edema

06

What researchers measure

Primary outcomes

  1. Transmural pressure

    Absolute difference between pulmonary capillary wedge pressure and right atrial pressure

    Time frame: During 5 minutes of rest in normoxia, after 15 minutes of exercise in normoxia, after 90 minutes of rest in hypoxia, after 15 minutes of exercise in hypoxia.

  2. Arterial oxygen saturation

    Time frame: During 5 minutes of rest in normoxia, after 15 minutes of exercise in normoxia, after 90 minutes of rest in hypoxia, after 15 minutes of exercise in hypoxia.

  3. Pulse oxygen saturation

    Time frame: During 5 minutes of rest in normoxia, after 15 minutes of exercise in normoxia, after 90 minutes of rest in hypoxia, after 15 minutes of exercise in hypoxia.

Secondary outcomes

  1. Gas exchange

    Oxygen uptake and carbon dioxide production

    Time frame: During 5 minutes of rest in normoxia, after 15 minutes of exercise in normoxia, after 90 minutes of rest in hypoxia, after 15 minutes of exercise in hypoxia.

  2. Arterio-venous oxygen different

    Time frame: During 5 minutes of rest in normoxia, after 15 minutes of exercise in normoxia, after 90 minutes of rest in hypoxia, after 15 minutes of exercise in hypoxia.

  3. Cardiac output

    Time frame: During 5 minutes of rest in normoxia, after 15 minutes of exercise in normoxia, after 90 minutes of rest in hypoxia, after 15 minutes of exercise in hypoxia.

  4. Right ventricular diameter

    Time frame: During 5 minutes of rest in normoxia, after 15 minutes of exercise in normoxia, after 90 minutes of rest in hypoxia, after 15 minutes of exercise in hypoxia.

  5. Tricuspid regurgitant jet velocity

    Time frame: During 5 minutes of rest in normoxia, after 15 minutes of exercise in normoxia, after 90 minutes of rest in hypoxia, after 15 minutes of exercise in hypoxia.

  6. Tricuspid annular plane systolic excursion

    Time frame: During 5 minutes of rest in normoxia, after 15 minutes of exercise in normoxia, after 90 minutes of rest in hypoxia, after 15 minutes of exercise in hypoxia.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07742540
Responsible party
Benjamin Levine (Professor of Medicine, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Aug 3, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Sep 15, 2028 (estimated)
Last update
Aug 3, 2026

Study contacts

Giorgio Manferdelli, Ph.D.
Contact
giorgio.manferdelli@utsouthwestern.edu
214-345-7134
Mary Childers
Contact
marychilders@texashealth.org
214-345-6459
Benjamin D. Levine, M.D.
principal investigator · The University of Texas Southwestern Medical Center Dallas

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion